Related to Shire Reports Positive Phase III Data to Support European Filing of ADHD Drug Vyvanse

• Movetis' Board Welcomes Shire's €428M Cash Takeover Bid
  
• Shire Gains EC Nod for Gaucher Disease Treatment
  
• Shire Pays Acceleron $45M Up Front for Neuromuscular Disease Candidates
  
• Researchers Provide First Tangible Evidence for Genetic Component in ADHD
  
• FDA Clears Shionogi’s Nonstimulant ADHD Therapy
  
• Shire Reports Positive Phase III Icatibant Data to Address Nonapprovable Status in U.S.
  
• Euthymics Bioscience Raises Series A Financing to $28M
  
• Cortex Regains Rights to Ampakine Compounds from Biovail
  
• Shire Negotiates Option to Heptares Preclinical-Stage A2A Antagonist Program
  
• Shire Buys Advanced BioHealing for $750M as Foundation for Regenerative Medicine Business
  
• DNA Genotek's Sample Collection Kit to Be Used in Substance Abuse Study Among ADHD Patients
  
• Genetic Studies Identify Copy Number Variants Associated with Both ADHD and Autism
  
• Glutamate Receptor Gene Changes Identified in ADHD
  
• Shire, Sangamo Ink $13M Up-Front Deal for ZFPs against Hemophilia and Monogenic Disorders
  
• EMA Green-Lights Shire’s Manufacturing Site in Lexington, MA, for Gaucher Therapy
  
• Shire Taps arGEN-X for Human Antibodies against Rare Genetic Disorders
  
• Shire to Buy FerroKin for $100M Cash to Acquire Phase II Iron Chelator
  
• Shire Licenses Heptares' Adenosine A_2A Receptor Antagonist for CNS Diseases
  
• Shire’s Mesalamine MMX Fails Primary Endpoint in Phase III Diverticulitis Study
  
• Shire to Purchase Substantially All Pervasis Assets to Fortify Regenerative Medicine Business